Malaysian company develops Covid-19 rapid test kits that can deliver results under 20 minutes
KUALA LUMPUR, Feb 26 — A homegrown diagnostic solution start-up has developed a digital rapid Covid-19 test kit — dubbed APTSENS — that can upload test results in real-time with geo-location data to cloud servers via a mobile app.
Kit ujian Covid hanya dalam masa 20 minit
KUALA LUMPUR, 26 Februari – Permulaan penyelesaian diagnostik tempatan telah mengembangkan kit ujian Covid-19 secara cepat dan digital – yang diberi nama APTSENS – yang dapat memuat naik hasil ujian dalam masa nyata dengan data lokasi geografi ke pelayan awan (cloud server) melalui aplikasi mudah alih.
CIP accelerate recipient, Biogenes Technologies develops a digital rapid COVID-19 test kit
“Although it has been extremely challenging for Biogenes to develop this test kit due to the lack of ecosystem in our domestic diagnostic sector, we have been very fortunate to receive support from Malaysian government agencies such as Platcom Ventures, CRADLE and NTIS.
COVID-19: Syarikat naungan AIM hasil vaksin, kit ujian
KUALA LUMPUR: Lima syarikat kini dalam pelbagai fasa bagi mengetengahkan produk perubatan untuk pengesanan virus dan klinikal, selain merintis usaha penyelidikan vaksin COVID-19.
Syarikat itu merangkumi Twin Catalyst Sdn Bhd, TTMC Sdn Bhd, Medical Innovation Ventures Sdn Bhd (Mediven), Biogenes Technologies Sdn Bhd dan IN3Bio.
AIM Ambil Pendekatan Inovatif Perangi Covid-19
Agensi Inovasi Malaysia (AIM) melalui empat syarikat Program Berimpak Tinggi 2 (HIP2) di bawah PlaTCOM Ventures Sdn Bhd dan sebuah syarikat pelaburan mengambil pendekatan inovatif untuk memerangi koronavirus (Covid-19) dengan menghasilkan produk perubatan dan klinikal selain memulakan penyelidikan vaksin.
Syarikat tersebut ialah Twin Catalyst Sdn Bhd, TTMC Sdn Bhd, Medical Innovation Ventures Sdn Bhd (Mediven), Biogenes Technologies Sdn Bhd dan IN3Bio.
15 Startups graduated from Antler's fourth Singapore cohort and COVID-19 Initiative
Bio Genes: A startup that produces aptamer-based (synthetic antibody) diagnostics products via an in-house proprietary technology platform.
Biogenes signs exclusive licensing agreement with IUKL
BANGI: Bioegenes Technologies Sdn Bhd (Biogenes), a Malaysian-based company in the field of molecular diagnostics and genomics has signed a licensing agreement with Infrastructure University Kuala Lumpur (IUKL) to commercialise Aptamer technology.